Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818844 · ClinicalTrials.gov registry record · Phase 4
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00818844 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 40 participants.
The verdict
NCT00818844, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
Interventions
- DRUG Nepafenac 0.1%
- OTHER BSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818844
The ClinicalTrials.gov registry entry for NCT00818844 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nepafenac 0.1% is the first listed.
NCT00818844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818844 about?
NCT00818844 is a clinical study titled "Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery". The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
What is the current status of trial NCT00818844?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2009-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00818844?
The interventions under investigation include: Nepafenac 0.1% (DRUG), BSS (OTHER).
Who is sponsoring clinical trial NCT00818844?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.